(159 days)
Not Found
Not Found
No
The summary describes a competitive immunoassay for drug detection, which is a standard biochemical method and does not mention any AI or ML components.
No
This device is an immunoassay used for the qualitative determination of the presence of major metabolites of various drugs in urine, which is a diagnostic function, not a therapeutic one.
Yes
The device is described as a "competitive immunoassay used for the qualitative determination of the presence of the major metabolites of amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, THC, tricyclic antidepressants, and propoxyphene in urine." The purpose of determining the presence of these substances in urine is to aid in the diagnosis of drug use.
No
The device description clearly indicates it is a competitive immunoassay, which is a laboratory test method involving chemical reactions and physical components, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative determination of the presence of the major metabolites of [various drugs] in urine." This is a classic description of an in vitro diagnostic test, as it analyzes a biological sample (urine) outside of the body to provide information about a person's health status (in this case, the presence of drugs).
- Device Description: The device description reiterates the same intended use, confirming its function as a test performed on a biological sample.
- Performance Studies: The performance studies described (Interfering Substances, Specificity/Cross-reactivity, Imprecision, Threshold validation) are all typical studies conducted to validate the performance of an in vitro diagnostic device.
- Predicate Devices: The mention of predicate devices (Triage® Drugs of Abuse Panel plus TCA and TDX/TDXFLX Propoxyphene test) which are also IVDs, further supports that this device falls into the same category.
The information provided clearly indicates that this device is designed to be used in vitro (outside the body) to diagnose or provide information about a person's health status by analyzing a biological sample.
N/A
Intended Use / Indications for Use
The Triage® Drugs of Abuse Panel Plus PPX is a competitive immunoassay used for the qualitative determination of the presence of the major metabolites of amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, THC, tricyclic antidepressants, and propoxyphene in urine.
Product codes
DKZ, DIS, JXM, LDJ, DIO, DJG, LCM, JXN, LFG
Device Description
The Triage® Drugs of Abuse Panel Plus PPX is a competitive immunoassay used for the qualitative determination of the presence of the major metabolites of amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, THC, tricyclic antidepressants, and propoxyphene in urine.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Interfering Substances: Substances that are commonly in human urine were tested for interference with results in samples spiked with drug 20% above the threshold concentration and samples spiked with drug 20% below the threshold concentration. None of the substances tested caused interference with the assav results.
Specificity/Cross-reactivity: Drugs and related substances were added to drug-free urine and tested using the Triage® Drugs of Abuse Panel plus PPX to determine the concentration that produces a positive result. The results are described in the labeling.
Imprecision: Imprecision was determined by measuring three contrived specimens with drug added at approximately 25% below the threshold concentration, the threshold concentration, and 25% above the threshold concentration. Three individuals evaluated each specimen ten times each day for three days. The precision results were consistent with the threshold validation results.
Previously established thresholds (amphetamines 1000, Threshold: methamphetamines 1000, barbiturates 300, benzodiazepines 300, tricvolic antidepressants 1000, phencyclidine 25, opiates 300, cocaine 300, and THC 50) were challenged by testing specimens containing each drug or drug metabolite spiked into drug-free urine at concentrations in increments of 25% above and 25% below the threshold. Each specimen was tested using the Triage® Drugs of Abuse Panel plus PPX. The data indicated that the device is able to detect drug concentrations near the threshold and that the thresholds are set appropriately.
Key Metrics
Not Found
Predicate Device(s)
Triage® Drugs of Abuse Panel plus TCA (Biosite Incorporated), TDX/TDXFLX Propoxyphene test (Abbott Laboratories)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3100 Amphetamine test system.
(a)
Identification. An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.(b)
Classification. Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
KC14247
JUN 0 3 2002
510(k) Summary
Triage® Drugs of Abuse Panel plus PPX
This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
510(k) Number: (To be determined)
A. Name and Address of Submitter
| Company Name: | Biosite Incorporated |
|---|---|
| Address: | 11030 Roselle Street |
| San Diego, CA 92121 | |
| Telephone: | (858) 455-4808 |
| Fax: | (858) 535-8350 |
| Contact Person: | Jeffrey R. Dahlen, Ph.D. |
| Date Summary Prepared: | 3/5/02 |
B. Device Names
-
- Trade Name
Triage® Drugs of Abuse Panel plus PPX
- Trade Name
-
- Common / Usual Name
Test System for Drugs of Abuse
- Common / Usual Name
-
- Classification Name
Amphetamine test system
- Classification Name
Barbiturate test system
Benzodiazepine test system
Cocaine and cocaine metabolite test system
Opiate test system
Cannabinoid test system
Tricyclic antidepressant drugs test system
Propoxyphene test system
1
Phencyclidine test system (Note: the phencyclidine test system has not been classified but has the same intended use to measure phencyclidine in serum or urine.
C. Predicate Devices
Triage® Drugs of Abuse Panel plus TCA (Biosite Incorporated), and the TDX/TDXFLX Propoxyphene test (Abbott Laboratories).
D. Device Description and Intended Use
The Triage® Drugs of Abuse Panel Plus PPX is a competitive immunoassay used for the qualitative determination of the presence of the major metabolites of amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, THC, tricyclic antidepressants, and propoxyphene in urine.
E. Summary of Performance Data
Interfering Substances: Substances that are commonly in human urine were tested for interference with results in samples spiked with drug 20% above the threshold concentration and samples spiked with drug 20% below the threshold concentration. None of the substances tested caused interference with the assav results.
Specificity/Cross-reactivity: Drugs and related substances were added to drug-free urine and tested using the Triage® Drugs of Abuse Panel plus PPX to determine the concentration that produces a positive result. The results are described in the labeling.
Imprecision: Imprecision was determined by measuring three contrived specimens with drug added at approximately 25% below the threshold concentration, the threshold concentration, and 25% above the threshold concentration. Three individuals evaluated each specimen ten times each day for three days. The precision results were consistent with the threshold validation results.
Previously established thresholds (amphetamines 1000, Threshold: methamphetamines 1000, barbiturates 300, benzodiazepines 300, tricvolic antidepressants 1000, phencyclidine 25, opiates 300, cocaine 300, and THC 50) were challenged by testing specimens containing each drug or drug metabolite spiked into drug-free urine at concentrations in increments of 25% above and 25% below the threshold. Each specimen was tested using the
2
Triage® Drugs of Abuse Panel plus PPX. The data indicated that the device is able to detect drug concentrations near the threshold and that the thresholds are set appropriately.
F. Conclusion
The results of performance studies demonstrate that the Triage® Drugs of Abuse Panel plus PPX is substantially equivalent to currently marketed devices.
3
Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three human profiles incorporated into its design. The eagle is facing right, and the profiles are stacked on top of each other. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 0 3 2002
Jeffrey R. Dahlen, Ph.D. Principal Scientist Clinical & Regulatory Affairs Biosite Diagnostics 11030 Roselle Street San Diego, CA 92121
Re: K014247
Trade/Device Name: Triage® Drugs of Abuse Panel plus PPX Regulation Number: 21 CFR 862.3100; 21 CFR 862.3150; 21 CFR 862.3170; 21 CFR 862.3870; 21 CFR 862.3250; 21 CFR 862.3650; 21 CFR 862.3700; 21 CFR 862.3910 Regulation Name: Amphetamine test system; Barbiturate test system; Benzodiazepine test system; Cannabinoid test system; Cocaine and cocaine metabolite test system; Opiate test system; Propoxyphene test system; Tricyclic antidepressant drugs test system Regulatory Class: Class II Product Code: DKZ; DIS; JXM; LDJ; DIO; DJG; LCM; JXN; LFG Dated: May 21, 2002
Received: May 22, 2002
Dear Dr. Dahlen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Steven Routman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
5
Page 1 of 1
510(k) Number (if known): (to be determined)
Device Name: Triage® Drugs of Abuse Panel Plus PPX
Indications For Use:
The Triage® Drugs of Abuse Panel Plus PPX is a competitive immunoassay used for the qualitative determination of the presence of the major metabolites of amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, THC, tricyclic antidepressants, and propoxyphene in urine.
Jean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K014247
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109) √
OR
Over-The Counter Use__________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)
డా